POLYCYCTIC KIDNEY DISEASE DIET

Tolvaptan

Tolvaptan is in clinical trials to decrease kidney cysts; it suppresses vasopressin, a cyst growth trigger. Drinking copious amounts of water, enough to exceed serum osmolality or about 3 liters/day, also suppresses vasopressin. Caffeine increases cyclicAMP, which in turn increases vasopressin.

Clinical Trial Tolvaptan

Tolvaptan"s side effects include increased thirst and increased urine output 4-5 liters per day (quarts). Individuals taking tolvaptan must keep up with this fluid loss. It has been found safe and effective in congestive heart failure and cirrhosis of the liver. TEMPO Phase II (2) the open label study, (every participant receives tolvaptan) is well underway. In the double blind study, phase III (3) some individuals receive tolvaptan others do not. Additional Tolvaptan trials have begun, including one by DaVita.

Tolvaptan Inclusion - exclusion

This third phase is to determine if Tolvaptan is effective in diminishing kidney cyst growth with PKD polycystic kidney disease. For this 1000 to 3000 volunteers will be needed to complete the fast track FDA approval granted by the FDA. Tolvaptan, a vasopressin 2 blocking drug for polycystic kidney disease is useful for both ADPKD, the autosomal dominant version and ARPKD, the autosomal recessive version. Tolvaptan (Otsuka Maryland Research Institute): Tolvaptan recently received fast track designation by the Food and Drug Administration because of its promise as a treatment for PKD. Tolvaptan a vasopressin inhibitor; a V2 Receptor blocker or a V2 drug. Surrounding kidney cysts is vasopressin and cyclic AMP. This triggers kidney cysts to fill with fluid, triggering kidney cyst expansion and growth. You may be wondering what can stimulate cyclic AMP to start this process causing kidney cysts to expand, fill with fluid and to multiply in numbers? Caffeine–caffeine from chocolate, de-caf coffee, de-caf tea, black tea, green tea, white tea, coffee in all its forms and all other products containing caffeine stimulates cyclic AMP. With congestive heart failure diuretics are useful but can lead to kidney problems. OPC 41061 or OPC 31026 (Tolvaptan) reduces fluid buildup, but it works differently from diuretics. OPC 41061 impedes the action of proteins in the kidney called vasopressin V2 receptors. These molecules respond to the hormone vasopressin, which signals cells to take up water. Blocking V2 receptors prevents fluid from accumulating. In addition to keeping patients on the dry side, tolvaptan also appears to stabilize salt imbalances, or hyponatremia (low sodium). Hyponatremia is an important predictor of poor outcomes in heart failure patients. To date doctors have no drugs to treat this condition -- a fact that could hasten the arrival of tolvaptan. Common side effects from OPC 31260 (the mother drug) are dry mouth, thirst, and increased urination. Possible things researchers will be looking at with Tolvaptan:

Tolvaptan looks promising as a treatment for ADPKD, though it remains in clinical trials.

We are  sharing our experiences with PLD Diet, an adjunct diet to consider  trying to complement a physician's prescribed medical therapy. Think  about testing this only with your doctor's prior knowledge, who can  adjust it, according to your own uniqueness by adding to your current  treatment.

Medical Disclaimer

Loading